We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Red Blood Cell Folate Level Is a Biomarker for Risk of Neural Tube Defects

By LabMedica International staff writers
Posted on 13 Aug 2014
The importance of maintaining high red blood cell (RBC) levels of folate during pregnancy to reduce risk of neural tube defects was confirmed in a review of results obtained by a large study of expectant mothers in China.

A team of American and Chinese researchers worked with results obtained from 247,831 participants in a prospective community intervention project in China (1993–1995) that was designed to prevent neural tube defects with 400 micrograms/day folic acid supplementation. More...
An additional 1194 participants came from a population based randomized trial (2003–2005) designed to evaluate the effect of folic acid supplementation on blood folate concentration among Chinese women of reproductive age.

Results revealed that the risk of neural tube defects was high at the lowest estimated RBC folate concentrations (for example, 25.4 neural tube defects per 10,000 births at 500 nanomoles/L) and decreased as estimated RBC folate concentration increased. Risk of neural tube defects was substantially reduced at estimated RBC folate concentrations above 1,000 nanomoles/L (for example, six neural tube defects per 10,000 births at 1,180 nanomoles/L).

The data derived from the Chinese studies was consistent with the existing literature on the link between folate and neural tube defects. Furthermore, neural tube defect risk estimates developed using the proposed model and population level RBC information were consistent with the prevalence of neural tube defects in the American population before and after food fortification with folic acid. Therefore, the authors concluded that RBC folate concentrations, as a biomarker for risk of neural tube defects, could be used to facilitate evaluation of prevention programs as well as to identify subpopulations at elevated risk for a neural tube defect affected pregnancy due to folate insufficiency.

The study, which was carried out by investigators at the [US] Centers for Disease Control and Prevention (Atlanta, GA, USA) and Peking University, Beijing, China), was published in the July 29, 2014, online edition of the British Medical Journal.

Related Links:
Centers for Disease Control and Prevention
Peking University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.